Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients treated with Vectibix™ (panitumumab)

GlaxoSmithKline (GSK) would like to inform healthcare professionals of the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with Vectibix™ (panitumumab). Based on data from a regular safety review, rare (≥1/10,000 to <1/1000 patients) cases of SJS and TEN have been reported in patients treated with Vectibix™. Healthcare professionals are advised to withhold or discontinue the use of Vectibix™ in their patients if SJS or TEN are suspected.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.